0001225208-16-027956.txt : 20160224
0001225208-16-027956.hdr.sgml : 20160224
20160224165046
ACCESSION NUMBER: 0001225208-16-027956
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160222
FILED AS OF DATE: 20160224
DATE AS OF CHANGE: 20160224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Prange Karen
CENTRAL INDEX KEY: 0001566083
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 161452632
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
4
1
doc4.xml
X0306
4
2016-02-22
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001566083
Prange Karen
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
SVP&Pres, Uro & Pelvic Health
Common Stock
2016-02-22
4
A
0
37212.0000
0.0000
A
60859.0000
D
Common Stock
2016-02-22
4
F
0
12094.0000
17.2600
D
48765.0000
D
Common Stock
1000.0000
I
By Parent
Deferred Stock Units
2016-02-22
4
A
0
11587.0000
0.0000
A
2021-02-22
Common Stock
11587.0000
11587.0000
D
Performance Share Units
2016-02-22
4
A
0
12508.0000
0.0000
A
2017-12-31
2017-12-31
Common Stock
12508.0000
12508.0000
D
Stock Option (Right to Buy)
17.2600
2016-02-22
4
A
0
33726.0000
0.0000
A
2026-02-22
Common Stock
33726.0000
33726.0000
D
On February 28, 2013, the reporting person was awarded a target number of performance share units under the Company's 2013 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2015 and was subject to the completion of the concurrent three-year individual service period. On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2017.
Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
/s/ Lee G. Giguere, Attorney-in-Fact
2016-02-24